AF
LCTX icon

Amalgamated Financial’s Lineage Cell Therapeutics LCTX Stock Holding History

Amalgamated Financial’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$23K Buy
+15,165
New +$23.5K ﹤0.01% 2699

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Amalgamated Financial's LCTX Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Lineage Cell Therapeutics (LCTX) in Q1 2022: 15,165 shares worth $23K. The stake represents ﹤0.01% of the portfolio and ranks #2699 among its holdings.

110 funds tracked by Wall St. Rank hold LCTX as of Q1 2022.

  • Amalgamated Financial held 15,165 shares of Lineage Cell Therapeutics worth $23K as of Q1 2022.
  • Lineage Cell Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • Lineage Cell Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2699 holding.
  • 110 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.